Martin Voss, MD, Memorial Sloan Kettering Cancer Center, highlights the research concerning IO-TKI combination, triplets, and other treatment approaches for renal cell carcinoma, as well as the encouraging research advances in rare subtypes of non-clear cell RCC.
Dr. Martin Voss on the Latest Research Updates in Treatments, Biomarkers, and More for RCC
By Martin Voss, MD - Last Updated: June 4, 2023Related Posts
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.